Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.75
EPGNF's Cash to Debt is ranked higher than
72% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. EPGNF: 3.75 )
EPGNF' s 10-Year Cash to Debt Range
Min: 1.73   Max: 11742.5
Current: 3.75

1.73
11742.5
Equity to Asset 0.41
EPGNF's Equity to Asset is ranked higher than
57% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. EPGNF: 0.41 )
EPGNF' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.98
Current: 0.41

0.39
0.98
F-Score: 3
Z-Score: -0.40
M-Score: -4.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -650.27
EPGNF's Operating margin (%) is ranked lower than
51% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. EPGNF: -650.27 )
EPGNF' s 10-Year Operating margin (%) Range
Min: -1166.79   Max: 130.51
Current: -650.27

-1166.79
130.51
Net-margin (%) -666.01
EPGNF's Net-margin (%) is ranked lower than
51% of the 292 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. EPGNF: -666.01 )
EPGNF' s 10-Year Net-margin (%) Range
Min: -1173.92   Max: 138.38
Current: -666.01

-1173.92
138.38
ROE (%) -194.16
EPGNF's ROE (%) is ranked lower than
52% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.47 vs. EPGNF: -194.16 )
EPGNF' s 10-Year ROE (%) Range
Min: -140.91   Max: 21.77
Current: -194.16

-140.91
21.77
ROA (%) -95.73
EPGNF's ROA (%) is ranked lower than
51% of the 302 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.41 vs. EPGNF: -95.73 )
EPGNF' s 10-Year ROA (%) Range
Min: -92.61   Max: 25.95
Current: -95.73

-92.61
25.95
ROC (Joel Greenblatt) (%) -1328.42
EPGNF's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. EPGNF: -1328.42 )
EPGNF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2903.81   Max: 249.81
Current: -1328.42

-2903.81
249.81
Revenue Growth (3Y)(%) -11.70
EPGNF's Revenue Growth (3Y)(%) is ranked higher than
59% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. EPGNF: -11.70 )
EPGNF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -45.3   Max: 17
Current: -11.7

-45.3
17
EBITDA Growth (3Y)(%) -23.30
EPGNF's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. EPGNF: -23.30 )
EPGNF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -30.2   Max: 57.9
Current: -23.3

-30.2
57.9
EPS Growth (3Y)(%) -28.40
EPGNF's EPS Growth (3Y)(%) is ranked higher than
60% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. EPGNF: -28.40 )
EPGNF' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.4   Max: 58
Current: -28.4

-28.4
58
» EPGNF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with EPGNF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 18.70
EPGNF's P/B is ranked lower than
51% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. EPGNF: 18.70 )
EPGNF' s 10-Year P/B Range
Min: 0.67   Max: 23.84
Current: 18.7

0.67
23.84
P/S 52.30
EPGNF's P/S is ranked lower than
56% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. EPGNF: 52.30 )
EPGNF' s 10-Year P/S Range
Min: 4.3   Max: 64.02
Current: 52.3

4.3
64.02
EV-to-EBIT -8.21
EPGNF's EV-to-EBIT is ranked lower than
51% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. EPGNF: -8.21 )
EPGNF' s 10-Year EV-to-EBIT Range
Min: -23.8   Max: 1.2
Current: -8.21

-23.8
1.2
Current Ratio 1.95
EPGNF's Current Ratio is ranked higher than
62% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. EPGNF: 1.95 )
EPGNF' s 10-Year Current Ratio Range
Min: 1.35   Max: 11.77
Current: 1.95

1.35
11.77
Quick Ratio 1.65
EPGNF's Quick Ratio is ranked higher than
62% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. EPGNF: 1.65 )
EPGNF' s 10-Year Quick Ratio Range
Min: 1.15   Max: 11.74
Current: 1.65

1.15
11.74
Days Inventory 400.67
EPGNF's Days Inventory is ranked higher than
61% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. EPGNF: 400.67 )
EPGNF' s 10-Year Days Inventory Range
Min: 7.67   Max: 256.65
Current: 400.67

7.67
256.65
Days Sales Outstanding 28.10
EPGNF's Days Sales Outstanding is ranked higher than
95% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 78.80 vs. EPGNF: 28.10 )
EPGNF' s 10-Year Days Sales Outstanding Range
Min: 29.38   Max: 110.31
Current: 28.1

29.38
110.31

Valuation & Return

vs
industry
vs
history
Price/Net Cash 38.40
EPGNF's Price/Net Cash is ranked higher than
79% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. EPGNF: 38.40 )
EPGNF' s 10-Year Price/Net Cash Range
Min: 1.08   Max: 296.4
Current: 38.4

1.08
296.4
Price/Net Current Asset Value 30.80
EPGNF's Price/Net Current Asset Value is ranked higher than
74% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. EPGNF: 30.80 )
EPGNF' s 10-Year Price/Net Current Asset Value Range
Min: 0.95   Max: 93.18
Current: 30.8

0.95
93.18
Price/Tangible Book 18.60
EPGNF's Price/Tangible Book is ranked higher than
57% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.76 vs. EPGNF: 18.60 )
EPGNF' s 10-Year Price/Tangible Book Range
Min: 0.89   Max: 17.49
Current: 18.6

0.89
17.49
Price/Median PS Value 2.90
EPGNF's Price/Median PS Value is ranked higher than
56% of the 341 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. EPGNF: 2.90 )
EPGNF' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 3.02
Current: 2.9

0.28
3.02
Earnings Yield (Greenblatt) -12.20
EPGNF's Earnings Yield (Greenblatt) is ranked higher than
53% of the 299 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. EPGNF: -12.20 )
EPGNF' s 10-Year Earnings Yield (Greenblatt) Range
Min: -12.2   Max: 12383
Current: -12.2

-12.2
12383

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:0QXH.UK, ECX.Germany,
Epigenomics AG was founded as a limited liability company (GmbH) in 1998. The Company develop and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer.
» More Articles for EPGNF

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK